Previous 10 | Next 10 |
United Therapeutics (NASDAQ: UTHR ) has closed its license agreement with Arena Pharmaceuticals (NASDAQ: ARNA ). More news on: United Therapeutics Corporation, Arena Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-ge...
RESEARCH TRIANGLE PARK, N.C. , Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on th...
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages, but profitability measu...
United Therapeutics Corp. (UTHR) Q3 2018 Earnings Call October 31, 2018 9:00 am ET Executives James Christopher Edgemond - United Therapeutics Corp. Martine A. Rothblatt - United Therapeutics Corp. Michael Benkowitz - United Therapeutics Corp. Analysts Chris Shibutani - Cow...
Thinly traded United Therapeutics ( UTHR -6.4% ) is down on average volume after posting Q3 results that were consistently down from a year ago. Highlights: More news on: United Therapeutics Corporation, Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read...
Gilead Sciences ( GILD -5.7% ) slumps on average volume. Investors appear disappointed with the (lack of) potential for its immuno-oncology partnership with Tango to rekindle growth. More news on: Gilead Sciences, Inc., United Therapeutics Corporation, Healthcare stocks news, Stocks on t...
United Therapeutics (NASDAQ: UTHR ): Q3 Non-GAAP EPS of $3.98 beats by $0.95 ; GAAP EPS of $2.42 misses by $0.61 . More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended September 30, 2018. "We are pleased to see continued growth in the number of U.S. pati...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...